Medical devices, healthcare technology and the business of care
510(k) clearance · K254074

TruPress

Procerus Enterprises · Decision date Sep 10, 2026

MEDTECHLEDGER EXPLANATIONK254074

What did the FDA decide?

FDA recorded a substantial equivalence (SESE) decision for K254074, TruPress, on 2026-09-10. The applicant of record is Procerus Enterprises, and the product is classified under product code DRS, described in the FDA listing as a transducer for extravascular blood-pressure measurement, within the Cardiovascular specialty. A SESE decision indicates clearance of the 510(k) submission; it is not premarket approval of a new device system.

The source record does not state the predicate device, the specific component or change under review, or any indications for use, and the linked FDA excerpt does not supply them. The excerpt also lists Ontogen Medtech and a Salt Lake City address alongside the applicant, but the record does not explain that relationship. Whether the submission covered a new transducer or a modification to an existing one therefore remains unknown from the available data.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Sep 10, 2026
FDA decision documents: 510(k) Premarket Notification - FDA

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K254074
Regulatory pathway
510(k) premarket notification
Product code
DRS
Decision code
SESE
Decision date
Sep 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transducer, Blood-Pressure, Extravascular.

Product code
DRS
FDA device class
2

FDA decision timeline

  1. K254074 received

    Application receipt date recorded by FDA.

  2. K254074 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Procerus Enterprises

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Salt Lake City, UT

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records